Patents Examined by Julie Wu
-
Patent number: 12043670Abstract: Antibodies, antigen-binding fragments, and conjugates (e.g., antibody-drug conjugates (ADCs) such as those comprising a splicing modulator) that bind to BCMA are disclosed. The disclosure further relates to methods and compositions for use in the treatment of cancer by administering a composition provided herein.Type: GrantFiled: June 4, 2021Date of Patent: July 23, 2024Assignee: Eisai R&D Management Co., Ltd.Inventors: Ryan Henry, Thiwanka Samarakoon, Nathan Fishkin, Ping Zhu, Ermira Pazolli, James Palacino, Juan C. Almagro
-
Patent number: 12030954Abstract: Provided is an antibody or an antigen-binding fragment thereof, having one or more properties selected from the group consisting of: 1) being capable of binding to an AXL protein by a KD value of 1×10?8 M or lower; 2) being capable of specifically recognizing an AXL protein expressed on a cell surface; and 3) being capable of mediating internalization after binding to the AXL protein expressed on the cell surface. The antibody may further used for constructing an immunoconjugate. The antibody and the immunoconjugate may inhibit the proliferation of tumor cells.Type: GrantFiled: May 28, 2019Date of Patent: July 9, 2024Assignees: HANGZHOU SUMGEN BIOTECH CO., LTD., SUMGEN MAB (BEIJING) BIOTECH CO., LTD.Inventors: Ming Lv, Xiaoran Ding, Shiwei Miao, Bin Tan, Xuegong Wang
-
Patent number: 12029736Abstract: The invention provides, camptothecins, camptothecin payloads, and camptothecin conjugates, methods of preparing and using, and intermediates useful in the preparation thereof. Also provided herein are methods of treating cancer and autoimmune diseases with the camptothecin conjugates described herein.Type: GrantFiled: February 25, 2021Date of Patent: July 9, 2024Assignee: MediBoston LimitedInventor: Wei Li
-
Patent number: 12011436Abstract: The present invention is related to compounds, methods, compositions and uses that are able to restore responsiveness to immunotherapy, in particular immune check point inhibitors or anti-cancer vaccine or to anti-angiogenesis treatment.Type: GrantFiled: November 1, 2018Date of Patent: June 18, 2024Assignees: CALLIDITAS THERAPEUTICS SUISSE SA, UNIVERSITY OF SOUTHAMPTONInventors: Philippe Wiesel, Freddy Heitz, Gareth Thomas, Christopher Hanley, Kirsty Ford
-
Patent number: 12011439Abstract: The present disclosure is drawn to the combination therapy of a C-C Chemokine Receptor 4 (CCR4) antagonist and one or more immune checkpoint inhibitors in the treatment of cancer.Type: GrantFiled: August 16, 2022Date of Patent: June 18, 2024Assignee: CHEMOCENTRYX, INC.Inventors: Shijie Li, Venkat Reddy Mali, Rajinder Singh, Ju Yang, Penglie Zhang
-
Patent number: 11987632Abstract: The present invention generally relates to antibodies that bind to HLA-A2/MAGE-A4, including multispecific antibodies e.g. for activating T cells. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies, and to methods of using them in the treatment of disease.Type: GrantFiled: December 17, 2020Date of Patent: May 21, 2024Assignee: Hoffmann-La Roche Inc.Inventors: Tina Weinzierl, Lydia Jasmin Hanisch, Alexander Bujotzek, Alejandro Carpy Gutierrez Cirlos, Stefan Klostermann, Christian Klein, Simon Patrick Keiser, Tanja Fauti, Estelle Marrer-Berger, Pablo Umaña
-
Patent number: 11976124Abstract: The present disclosure provides isolated monoclonal antibodies or an antigen-binding portion thereof that specifically bind to CD40 preferably human CD40 with high affinity, and that function as CD40 agonists. The disclosed invention also relates to antibodies that are chimeric, humanized, bispecific, derivatized, single chain antibodies or portions of fusion proteins. Nucleic acid molecules encoding the antibodies of the disclosed invention, hybridoma, and methods for expressing the antibodies of the disclosed invention are also provided. Pharmaceutical compositions comprising the antibodies of the disclosed invention are also provided. This disclosure also provides methods for regulating humoral and cellular immune responses, as well as methods for treating cancer using an anti-CD40 agonist antibody of the disclosed invention.Type: GrantFiled: December 23, 2020Date of Patent: May 7, 2024Assignee: ABVISION, INC.Inventors: Chang-Hsin Chen, Gloria Zhang, Guochen Yan, Cheng-Chi Chao
-
Patent number: 11976128Abstract: The present disclosure is directed to antibodies binding to PD-L2 and methods of using such antibodies to treat cancers, such as those that express or overexpress PD-L2.Type: GrantFiled: March 15, 2019Date of Patent: May 7, 2024Assignee: Board of Regents, The University of Texas SystemInventors: Michael A. Curran, Ashvin R. Jaiswal, Dongxing Zha, Kui Voo, Carlo Toniatti, Bianka Prinz, Nadthakarn Boland
-
Patent number: 11965037Abstract: Provided is an anti-HER3 humanized monoclonal antibody. The antibody binds HER3 antigen, has high affinity and biological activity and low immunogenicity, and is stable in structure. The antibody can be used for preparing drugs for preventing or treating HER3-related diseases.Type: GrantFiled: July 17, 2019Date of Patent: April 23, 2024Assignee: SHANGHAI INSTITUTE OF BIOLOGICAL PRODUCTS CO., LTD.Inventors: Aidong Qu, Hongyuan Liang, Fanhong Xu, Aoxiang Li, Lina Wu, Jingye Zhu, Jianhua Qiu, Jin Lu, Lin Zhang, Xin Zhao, Xiaofei Song
-
Patent number: 11945861Abstract: Provided are novel IFB-a binding molecules of human origin, particularly human-derived anti-IFN-? antibodies as well as IFN-? binding fragments, derivatives and variants thereof. In addition, pharmaceutical compositions, kits, and methods for use in diagnosis and therapy are described.Type: GrantFiled: January 21, 2021Date of Patent: April 2, 2024Assignee: IMMUNOQURE AGInventors: Syeda F. Y. Haque, Adrian Hayday, Kai Kisand, Kai Krohn, Annalisa Macagno, Steffen Meyer, Paert Peterson, Mike Rothe, Philip Vlaicu, Martin Woodward
-
Patent number: 11939381Abstract: The present invention relates to bispecific antibodies that antagonize human PD-1 and agonize human CD137, and may be useful for treating solid and hematological tumors alone and in combination with chemotherapy and ionizing radiation.Type: GrantFiled: July 12, 2019Date of Patent: March 26, 2024Assignee: Eli Lilly and CompanyInventors: Stephen J. Demarest, Yiqing Feng, Juqun Shen, Yang Shen, Stephanie Marie Truhlar
-
Patent number: 11939386Abstract: Disclosed are a new AXL-targeting monoclonal antibody and antibody-drug conjugate. Also disclosed is a method for preparing said antibody and antibody-drug conjugate. The AXL antibody of the present invention can bind with purified human AXL protein and multiple AXL on tumor cell surface with high effectiveness and high specificity. Said humanized antibody also has high affinity and low immunogenicity. Said AXL antibody-drug conjugate has markable performance against tumors having high AXL expression.Type: GrantFiled: May 10, 2019Date of Patent: March 26, 2024Assignee: Shanghai Institute of Materia Medica, Chinese Academy of SciencesInventors: Ke Yu, Jingkang Shen, Tao Meng, Jinpeng Pei, Lanping Ma, Xin Wang, Rui Jin, Zhiyan Du, Lin Chen, Ting Yu, Yongliang Zhang
-
Patent number: 11919960Abstract: The present disclosure provides antibody sequences found in antibodies that bind to human CD25. In particular, the present disclosure provides sequences of anti-human CD25 antibodies, which do not block the binding of CD25 to IL-2 or IL-2 signalling. Antibodies and antigen-binding portions thereof including such sequences can be used in 5 pharmaceutical compositions and methods of treatment, in particular for treating cancer.Type: GrantFiled: March 13, 2019Date of Patent: March 5, 2024Assignees: Tusk Therapeutics Ltd., Cancer Research Technology LimitedInventors: Anne Goubier, Beatriz Goyenechea Corzo, Josephine Salimu, Kevin Moulder, Pascal Merchiers, Sergio Quezada
-
Patent number: 11912747Abstract: Described herein are recombinant chimeric proteins comprising a double stranded RNA (dsRNA) binding domain and a cancer-cell targeting domain for targeting of dsRNA to cancer cells. Methods of use of the described chimeric proteins are also provided herein.Type: GrantFiled: December 15, 2016Date of Patent: February 27, 2024Assignee: TARGIMMUNE THERAPEUTICS AGInventors: Alexander Levitzki, Yael Langut
-
Patent number: 11891449Abstract: The present application provides a recombinant fusion protein containing an anti-CD24 antibody or an antibody fragment thereof, with at least one paratope of the anti-CD24 antibody or antibody fragment thereof linked via a linker to an extracellular Ig-like domain of a signal-regulatory protein (SIRP) at N-terminus of a heavy chain or a light chain constituting that paratope, wherein the recombinant fusion protein can bind to CD47, CD24 and FcR simultaneously. The present application also provides a nucleic acid molecule encoding the recombinant fusion protein, an expression vector containing the nucleic acid molecule, a method for producing the recombinant fusion protein and a method for treating a disease associated with over expression of CD47 and/or CD24 using the recombinant fusion protein.Type: GrantFiled: December 6, 2021Date of Patent: February 6, 2024Assignee: IMMUNEONCO BIOPHARMACEUTICALS (SHANGHAI) INC.Inventors: Wenzhi Tian, Song Li, Dianze Chen
-
Patent number: 11884723Abstract: The invention is in the field of immunotherapy. The present invention provides antibodies useful in therapeutic and diagnostic applications targeting human SIRPa, said antibodies enhancing the cross-presentation of antigens to T cells. The invention also provides antibodies against specific isoforms of SIRP a and able to disrupt the interaction between those isoforms of SIRP a and human CD47 for use in treating or preventing a disease, or diagnostic applications, and methods for producing and/or selecting anti-human SIRPa antibodies that bind with different affinities to various isoforms of human SIRP members.Type: GrantFiled: March 13, 2019Date of Patent: January 30, 2024Assignee: OSE IMMUNOTHERAPEUTICSInventors: Nicolas Poirier, Vanessa Gauttier, Caroline Mary, Sabrina Pengam, Bernard Vanhove
-
Patent number: 11884729Abstract: The present disclosure provides antibodies that specifically bind to L1CAM and compositions comprising such antibodies. Also provided herein are methods for preventing or treating diseases or conditions which comprise a tumor using the anti-L1CAM antibodies.Type: GrantFiled: June 27, 2019Date of Patent: January 30, 2024Assignee: ApitBio, IncInventors: Hyo Jeong Hong, Heesu Chae, Jisu Hong
-
Patent number: 11879012Abstract: This invention relates generally to a method of inhibiting epithelial cell proliferation including the treatment of conditions associated with aberrant epithelial cell proliferation in mammals, including animals and humans. The present invention is particularly relevant for the treatment of cancer.Type: GrantFiled: March 4, 2019Date of Patent: January 23, 2024Assignees: METRO NORTH HOSPITAL AND HEALTH SERVICEInventors: Peter Gillies, Damien G. Harkin, Neil A. Richardson
-
Patent number: 11866500Abstract: Disclosed is the use of a combination of an anti-PD-1 antibody and a VEGFR inhibitor in the preparation of a drug for treating cancers.Type: GrantFiled: November 12, 2021Date of Patent: January 9, 2024Assignees: Suzhou Suncadia Biopharmaceuticals Co., Ltd., Jiangsu Hengrui Medicine Co., Ltd., Shanghai Hengrui Pharmaceutical Co., Ltd.Inventors: Xing Sun, Guoqing Cao, Changyong Yang, Lianshan Zhang, Yong Guo
-
Patent number: 11851494Abstract: The present disclosure provides antibody sequences found in antibodies that bind to human CD25. In particular, the present disclosure provides sequences of anti-human CD25 antibodies, which do not block the binding of CD25 to IL-2 or IL-2 signalling. Antibodies and antigen-binding portions thereof including such sequences can be used in pharmaceutical compositions and methods of treatment, in particular for treating cancer.Type: GrantFiled: March 13, 2019Date of Patent: December 26, 2023Assignees: Tusk Therapeutics Ltd., Cancer Research Technology LimitedInventors: Anne Goubier, Beatriz Goyenechea Corzo, Josephine Salimu, Kevin Moulder, Pascal Merchiers, Sergio Quezada